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Abstract
Background: Nowadays no researches has been performed on fatty acid profile (FA) and desaturase activity in
metabolically healthy obesity (MHO). The aim of this study was to assessed gender and BMI-related difference in FA,
estimated desaturase activities and the efficacy on metabolic changes produced by 2-months well-balance diet in
MHO subjects.
Methods: In 103 MHO subjects (30/73 M/F; age:42.2 ± 9.5) FA, estimated desaturase activity, body composition
(by DXA), Body Mass Index (BMI), lipid profile, adipokines (leptin, adiponectin, grelin, glucagon-like peptide-1),
insulin resistence (by Homestasis metabolic assessment), C-reactive proteine, Atherogenic index of plasma (AIP)
and Body Shape Index (ABSI) have been assessed. Gender and BMI related difference have been evaluated and
the efficacy produced by 2-months well-balance diet has been considered.
Results: At baseline, obese subjects, compared to overweight, show a significantly higher oleic (p <0.050),
monounsaturated fatty acids (p <0.040), C18:0 delta-9 desaturase activity (D9D) (p <0.040) and lower linoleic acid
(p <0.020), polyunsaturated fatty acids (p <0.020) and n-6 LCPUFA (p <0.010). Concerning gender-related difference,
women show a significantly higher arachidonic acid (p <0.001), polyunsaturated fatty acids (p <0.001), n-6 LCPUFA
(p <0.002), and lower monounsaturated fatty acids (p <0.001), D6D activity (p <0.030), C18:0 D9D (0.000) and C16:0 D9D
(p <0.030). The 2-months diet was associated with a significantly increase in arachidonic acid (p = 0.007), eicosapentaenoic
acid (p = 0.030), docosahexaenoic acid (p <0.001), long chain omega 3 polyunsaturated fatty acids (n-3 LCPUFA)
(p <0.001), delta-5 desaturase activity (D5D) (p = 0.002), glucagon like peptide-1 (p <0.001) and a significant decrease in
palmitoleic acid (p = <0.030), n-6/n-3 LCPUFA (p <0.001), insulin resistance (p = 0.006), leptin (p = 0.006), adiponectin
(p <0.001), grelin (p = 0.030), CRP (p = 0.004), BMI (p <0.001) and android fat mass (p <0.001).
Conclusions: The balanced diet intervention was effective in improving metabolic indices.
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Introduction
Metabolically healthy obesity (MHO) is a phenotype
related to a subgroup of obese individuals who do
not have insulin resistance, lipid disorders or hyper-
tension [1]. Selection criteria for MHO individuals
were partially based on the National Cholesterol Edu-
cation Program's Adult Treatment Panel III report
(ATP III) for lipid profiles (triglycerides: ≤.7 mmol/l,
total cholesterol: ≤5.2 mmol/l, HDL-cholesterol:
≥1.3 mmol/l and LDL-cholesterol: ≤2.6 mmol/l) and
on the study of Karelis [2] for insulin sensitivity
(HOMA < =1.95). When 4 out of 5 criteria are met, a
diagnosis of the MHO individual could be made, as
suggested by Karelis [2].
MHO is an important, emerging phenotype with
disease risks somewhere intermediate between
healthy, normal weight, and unhealthy, obese individ-
uals. From a clinical perspective, if this subgroup of
obese individuals really do not have increased risk of
metabolic syndrome or cardiovascular disease (CVD),
is still under discussion [1]. People from the MHO
are apparently protected from metabolic complica-
tions of obesity and do not have higher risk of inci-
dent of chronic kidney disease [3].
On the contrary recent study have demonstrated in
MHO an increased incident of fatty liver [4].
And Appleton and collaborators have demonstrated
the development of cardiometabolic abnormalities in
one-third of MHO studied subjects with a significantly
increased risk of diabetes [5].
Conversely other authors indicates that MHO subjects
have a CVD risks similar to those of normal-weight sub-
jects [6, 7]. Some findings indicate that the CVD risk
attributable to obesity requires the concomitant pres-
ence of metabolic risk factors and may be related to dif-
ferences in body composition, fitness, and inflammatory
profiles [8–10].
Studies in small selected samples of postmenopausal
(cessation of menstruation for more than 1 year and a
follicle-stimulating hormone level of at least 30 U/L)
obese women also suggest that the MHO may have
more favorable inflammatory profiles [11], less visceral
fat, and possibly less hepatic fat [12] than their counter-
parts with insulin resistance and other metabolic abnor-
malities [13].
Finally Appleton demonstrated that MHO phenotype
is transient and can move to metabolically at risk obese
(MRO) one depending on life style and exposure to haz-
ardous adipokines, indicating that target interventions
might be useful to prevent MRO related risks.
On the contrary, there are no data on plasma fatty acid
profile and desaturase activities in metabolically healthy
obesity (MHO), and their possible role as MHO pheno-
type markers and associated risks of metabolic disorders.
In fact, various studies have demonstrated that insulin
resistance and insulin resistant states are often associated
with an alteration of fatty acid (FA) pattern in plasma,
characterized by an increased proportion of palmitic
(C16:0) and a low proportion of linoleic (C18:2 omega-6,
LA) acids; the distribution of other fatty acids indicates
also an increased activity of delta-9 and delta-6 desa-
turases [14].
Fatty acids play a key role in energy balance, carbohy-
drate and lipid metabolism, and regulation of gene tran-
scription [15]. The plasma fatty acid profile is influenced
by two factors equally important: dietary fat intake and
endogenous fatty acid metabolism related also to desatur-
ase enzymes, which regulate the degree of unsaturation
of lipids throughout the body [16]. The delta-9 desaturase
(D9D) catalyses the conversion of palmitic and stearic
acids (C18:0) into monounsaturated fatty acid (MUFA),
palmitoleic acid (C16:1) and oleic acid (C18:1, OA)
respectively. It has been observed that delta-9 desaturase
activity is high in conditions like diabetes, atherosclerosis,
obesity and metabolic syndrome [17]. Delta-9 desaturase,
also called stearoyl-CoA desaturase (SCD), is highly
regulated and very sensitive to external changes, e.g.,
dietary factors and hormones. The changes in its activity
are mirrored in the composition of cholesteryl esters,
triglycerides and membrane phospholipids [18]. Delta-5
Desaturase (D5D) and delta-6 desaturase (D6D) are
key enzymes in polyunsaturated fatty acids (PUFA) me-
tabolism that catalyze the conversion of LA into arachi-
donic acid (C20:4 omega-6, AA) and that of alpha-
linolenic acid (C18:3, omega-3, ALA) into eicosapenta-
enoic acid (C20:5 omega-3, EPA) and docosahexaenoic
acid (C22:6 omega-3, DHA).
Gender differences have been reported in obese sub-
jects for D9D, with higher activity in women than men.
Moreover, women have been reported to have signifi-
cantly higher levels of D6D activity than men [19].
Controlled fatty acid intake might influence plasma
fatty acid profile and desaturase enzyme activities in
obese subjects with typical metabolic disorders asso-
ciated with obesity [20, 21]. Studies demonstrated
that replacing saturated fatty acids in the diet with
either MUFA [20] or PUFA [21] resulted in changes
in serum fatty acid profile and improved insulin
sensitivity.
Given this background, the aim of this study was to
investigate if 2-months diet intervention in a group of
metabolically healthy obese men and women is able
to influence plasma fatty acid profile, estimated desa-
turase activities and adipokines. Moreover, the influ-
ence of gender and body mass index (BMI) on plasma
FA pattern and desaturase activities was evaluated.
For the study a 2 months dietetic intervention was
chosen as it is known that the fatty acid composition
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in serum lipid esters mirrors to a certain extent the
dietary fatty acids composition during the last 6–8
weeks [22, 23].
Materials and methods
Subjects
The study was performed following approval of the
Ethic Committee of the Department of Internal
Medicine and Medical Therapy, University of Pavia.
Subjects gave their written consent to the study. All
subjects had to give complete medical histories, and
all underwent physical examination, anthropometric
assessment and routine laboratory tests. Selection
criteria for MHO individuals were partially based
on the National Cholesterol Education Program's
Adult Treatment Panel III report (ATP III) for lipid
profiles (triglycerides: ≤.7 mmol/l, total cholesterol:
≤5.2 mmol/l, HDL-cholesterol: ≥1.3 mmol/l and
LDL-cholesterol: ≤2.6 mmol/l) and on the study of
Karelis [2] for insulin sensitivity (HOMA < =1.95).
When 4 out of 5 criteria are met, a diagnosis of
the MHO individual could be made, as suggested by
Karelis [2].
Moreover, patients were excluded from the study if they
met the Diagnostic and Statistical Manual-IV (DSM-IV)
criteria for a current diagnosis of major depressive dis-
order as determined by the Structured Clinical Interview
for DSM-IVAxis 1 Disorders (SCID-1) [24].
Subjects also were excluded if they were taking
medications for weight loss, for control of cholesterol
and TG, for anti-inflammatory purpose, or were
pregnant or lactating, or if they had entered meno-
pause. All participants agreed to refrain from partici-
pating in any other weight loss program. Alcohol
intake, smoking habits and physical activity were
recorded. Sedentary and non-smoking subjects, who
did not drink more than 6 glasses (glass: 125 ml) of
wine a week and did not drink hard liquor (alcohol
content of at least 20 % Alcohol by volume), were
admitted to the study.
Procedures and study design
After 12 hours of fasting and abstinence from water
since midnight, the subjects arrived at around 8:00 AM,
using motorised transportation, at the Endocrinology
and Clinical Nutrition Unit of Azienda di Servizi alla
Persona di Pavia, University of Pavia (Italy).
Blood samples were taken for the routine measure-
ments and in order to assess leptin, adiponectin, ghrelin,
insulin, glycerol, total free fatty acid content. Body com-
position was determined by dual energy X-ray absorpti-
ometry (DXA). The same evaluations were assessed after
2 months’ well balance intervention diet.
Body composition measurement
Body composition was determined using a Lunar
Prodigy DXA (GE Medical Systems, Waukesha,
Wisconsin). The in vivo coefficients of variation were
4.2 and 0.48 % for fat and lean body mass respect-
ively. Central fat (an approximation of visceral fat)
was evaluated using always Dual-energy X-ray ab-
sorptiometry (DXA). This assessment consisted of
measuring the fat percentage within a defined rectangle,
from the upper edge of the second lumbar vertebra to the
lower edge of the fourth lumbar vertebra. The vertical
sides of this rectangular area were the continuation of the
lateral sides of the rib cage [25].
Anthropometry, weight-loss program and food intake
Nutritional status was analyzed using anthropometric
measurements at baseline and after 2 months in both
groups. Body weight and height were measured and
the Body Mass Index (BMI) was calculated (kg/m2).
Skinfold thicknesses (biceps, triceps, suprailiac, sub-
scapular) were measured twice using a Harpenden
skinfold caliper at 5 min intervals at each site, fol-
lowing a standardized technique [26]. Sagittal abdom-
inal diameter was assessed at the L4–5 level in the
supine position and waist girth was also measured.
Anthropometric variables were measured by a single
investigator. Body weight reduction was induced by a
low-energy mixed (55 % carbohydrates, 30 % lipids
and 15 % proteins) diet providing 600 kcal less than
individually estimated energy requirements based on
the measured Resting Energy Expenditure (REE). The
individual energy requirements were estimated by
indirect calorimetry (ventilated hood system) at base-
line and multiplied by a factor of 1.3, corresponding
to a low physical activity level. The energy content
and macronutrient composition of the diets adhered
to the nutritional recommendations of the American
Diabetes Association [27–29] with limit fat intake
to <25 % of total calories (with limit saturated fat to
<7 % of total calories and dietary cholesterol
to <200 mg/day), protein intake to 15–20 % with
1.0 g kg body wt−1 day−1 and carbohydrate to
55–60 % with 14 g dietary fiber/1000 kcal.
These diets were designed to achieve weight losses of
0.5 to 1 kg per week and they are considered to be a
low-risk intervention [28]. Individual diet plans were
drawn up for each subject by the research dietitian. To
optimize compliance, dietary instructions were rein-
forced each week by the same research dietician. Each
consultation included a nutritional assessment and
weighting. A 3-day weighed-food record of 2 weekdays
and 1 weekend day was performed before the study and
during the last week of intervention. One-day weighed-
food records were completed in weeks 2, 5 and 7. Low
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energy diets and dietary records were analyzed using a
food-nutrient database (Rational Diet, Milan, Italy). In
order to assess compliance to the weight-reduction
programme, a 24-hour dietary summary was assessed
by the nutritionist at the end of the study.
Biochemical analyses
Fasting venous blood samples were drawn between
8:00 and 10:00 AM in a sitting position. Blood collec-
tion and handling were carried out under strictly
standardized conditions and in line with manufac-
turers’ recommendations. The blood samples required
for Clinical Chemistry parameters were collected into
evacuated tubes without anticoagulant, left for 1 h at
room temperature, and then centrifuged for 15 min at
1500 × g. Following centrifugation, the serum was
transferred into plastic tubes, rapidly frozen and
stored at −80 °C until analysis (less than 1 month
later). Moreover whole blood, collected into tubes
with EDTA as anticoagulant, was used for haemato-
logical parameters. The C-reactive protein (CRP) was
determined by Nefelometric High Sensitivity CRP
(Dade Behring, Marburg, Germany).
Apolipoprotein (apo)A-I and apoB were enzymati-
cally measured using an autoanalyzer (Hitachi, Tokyo,
Japan).
To determine insulin resistance, subjects were
instructed to fast for 12 h before blood was drawn.
Furthermore, the subjects refrained from any kind of
exercise for 48 h prior to the study. Female subjects
were tested during the early follicular phase of their
menstrual cycle (days 3–10). Insulin resistance was
evaluated using the Homeostasis Model Assessment
(HOMA) [30] using the following formula:
HOMA‐IR ¼ ½ðfasting insulin; μU=mLÞ 
plasma glucose; mmol=Lð Þ=22:5
Atherogenic index of plasma (AIP) [31], and Body
Shape Index (ABSI) [32] have been calculated.
Serum concentrations of FFA and glycerol were
determined by a quantitative colorimetric assay (BioAssay
Systems, Hayward, CA); the minimum detectable concen-
trations are 0.007 mM/L and 0.01 mM/L respectively.
Intra- and inter-assay coefficients of variation are <3 and
<5 % respectively for both measurements.
Plasma acylated and unacylated ghrelin levels were
measured using an enzyme immunometric assay (EIA)
based on a double-antibody sandwich technique
(BioVendor, Brno, CZECH REPUBLIC). Blood samples
were drawn into a cold syringe and added to chilled
Vacutainer® EDTA-plasma tubes, according to the
manufacturer’s recommendations. The limit of detec-
tion for acylated ghrelin is 1.5 pg/mL (incubating for
20 h at +4 °C), and the intra- and inter-assay coefficients
of variation are 7.5 and 8.3 % respectively. The mini-
mum detectable concentration of unacylated ghrelin is
2 pg/mL (incubating for 20 h at +4 °C); the intra- and
inter-assay coefficients of variation are 6.3 and 7 %
respectively.
Serum adiponectin levels were measured using an
enzyme-linked immunosorbent assay (ELISA) (R&D
Systems, Inc., Minneapolis, MN, USA); the minimum
detectable concentration is 0.246 ng/mL. The intra-
and inter-assay coefficients of variation are 3.5 and
6.5 % respectively.
Serum leptin levels were measured using an enzyme-
linked immunosorbent assay (ELISA) (R&D Systems,
Inc., Minneapolis, MN, USA); the minimum detectable
concentration is <7.8 pg/mL. Intra- and inter-assay coef-
ficients of variation are 3.1 and 4.3 % respectively.
Lipid analyses
Regarding plasma fatty acid profile, the analysis was carried
out blind to the subject status. Plasma was stored at −80 °C
until used for analysis. Lipids were extracted with different
chloroform/methanol mixtures according to Folch [33] and
fractionated by HPLC-ELSD and analyzed as previously
describe [34, 35].
Fatty acid composition of whole plasma was deter-
mined by gas-chromatographic analysis. The fatty acid
methylesters, obtained after trans-derivatization with
sodium methoxide in methanol 3.33 % w/v, were
injected into gas chromatograph (Agilent Technologies
6850 Series II) equipped with a flame ionization
detector (FID) under the following experimental condi-
tions: capillary column: AT Silar length 30 m, film thick-
ness 0.25 μm, Gas carrier: helium, temperature: injector
250 °C, detector 275 °C, oven 50 °C for 2 min, rate of
10 °C min-1 until 200 °C for 20 min. A standard mixture
containing methyl ester fatty acids was injected for
calibration.
Estimated desaturase activity
Desaturase activity was estimated indirectly as a prod-
uct/precursor fatty acid ratio in serum phospholipids
and cholesterol esters, which reflects both dietary
intake and endogenous metabolism of fatty acids [16].
Statistical analysis
Data on fatty acid profile and estimated desaturase
activities were described as mean ± standard deviation
(SD) or median and 25th-75th percentiles (if skewed);
they were compared between genders and between
BMI groups (overweight/obese patients) with the un-
paired Student t test or Mann Whitney U (if skewed)
test. The mean difference between groups and its
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95 % confidence interval (CI) were computed. Overall
changes from baseline to the 2-months assessment
were estimated with the paired Student t test or the
sign test (if skewed); the mean (median) change was
computed together with its 95 % CI. A multivariable
regression model for repeated was fitted to control
the change from baseline for gender and BMI group.
Huber White robust standard errors were computed
to account for intra-patient correlation.
Stata 13.1 (StataCorp, College Station, TX, USA) was
used for computation. All tests were 2-sided. A p-value <
0.05 was considered statistically significant.
Results
Eight hundred ninety two subjects were screened for
eligibility. One hundred and three metabolically
healthy obese subjects were included in the study, out
of 107 eligible participants (Fig. 1). The baseline char-
acteristics of the group are summarized in Table 1,
together with their plasma fatty acid composition.
Table 2 shows the baseline gender differences in fatty acid
profile and estimated desaturase activities. We observed
that women, compared to men, show a significantly
higher content of arachidonic acid (p = 0.0003), total
polyunsaturated fatty acids (PUFA) (p = 0.0015), omega-6
PUFA (p = 0.0021), and a lower value of monounsaturated
fatty acids (p = 0.0001), of delta-6 desaturase (p = 0.03),
C18:0 delta-9 desaturase (p = 0.001) and C16:0 delta-9
desaturase (p = 0.03) activities.
The baseline differences in fatty acid profile and
estimated desaturase activities between overweight
(BMI < 30: 55 subjects) and obese (BMI > 30: 48
subjects) subjects are illustrated in Table 3. We
observed that obese subjects, compared to over-
weight subjects, show a significantly higher value of
oleic acid (C18:1) (p = 0.05), monounsaturated fatty
acids (p = 0.03), C18:0 delta-9 desaturase activity
(p = 0.04) and a lower value of linoleic acid (C18:2,
LA) (p = 0.02), total PUFA (p = 0.02) and omega-6
PUFA (p = 0.01).
Table 4 shows the macronutrient intake, assessed by 3-
day weighed-food record of 2 week days and 1 weekend
day, before and after of 2-months of well balanced inter-
vention diet.
107 eligible MHO subjects: fulfilled inclusion criteria 
103 allocated to dietary 
intervention
Followed up at 
week 8: n = 103
103 analysed
892 overweight and obese subjects assessed for eligibility
103 included in the study
Fig. 1 Flow diagram of the subjects studied
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As shown in Table 5, after 2-months of intervention
we observed a significant increase in all subjects of AA
(p = 0.007), EPA (p = 0.03), DHA (p <0.001), omega-3
PUFA (p <0.001) content, and of delta-5 desaturase activ-
ity (p <0.05). Furthermore we demonstrated a significant
decrease in palmitoleic acid (p = 0.038) and n-6 LCPUFA/
n-3 LCPUFA ratio (omega-6/omega-3, p = 0.001).
The results shown in Table 6 confirm the efficacy
of 2-months well-balance intervention diet on meta-
bolic changes: we observed a significant increase of
glucagon like peptide-1 (p = 0.000) and a significant
decrease of insulin resistance, assessed by HOMA (p
= 0.006), leptin (p = 0.006), adiponectin (p = 0.0001),
grelin (p =0.03), C-reactive protein (p = 0.004), ABSI
(p = 0.000), BMI (p = 0.000) and android fat mass
by DXA (p = 0.000). These differences were maintained
after adjusting for gender and BMI groups in the multivar-
iable regression model. On the contrary, no significant
correlations were found between the metabolic parame-
ters measured.
Discussion
This study evaluated for the first time in the litera-
ture, the plasma fatty acid composition and the esti-
mated desaturase activities, and their correlation with
gender, obesity and diet intervention, in a population
of metabolically healthy overweight and obese sub-
jects. Until now, even the most recent studies on this
topic have focused on subjects presenting or with in-
creased metabolic syndrome [36] or diabetes prob-
ability [37].
The main result of this study is that 2-months
of prudent diet intervention was associated with a
significantly and independent improvement in meta-
bolic indices, in particular a significant decrease in
PCR, HOMA, n-6 LCPUFA/n-3 LCPUFA, leptin,
grelin, palmitoleic acid and a significant increase in
delta-5 desaturase activity, accompanied by a BMI
and android fat mass reduction.
The improvement of these metabolic indices, sec-
ondary to the change in diet and weight loss, is in
agreement to what was already demonstrated in the
literature in obese subjects [38, 39]. Moreover, these
changes were generally similar for men and women
and for patients with higher and lower BMI, data not
shown.
Our findings reinforce the hypothesis that also MHO
subjects would benefit from a weight loss dietetic
intervention.
With regard in particular to the plasma fatty acid pro-
file, the palmitoleic acid decrease is an intriguing result
of the study, since it is interesting to note that palmito-
leic acid was also reported as a marker of cardiovascular
disease risk [40].
Table 1 Baseline characteristics of the studied group
Variable MEAN ± DS
Age (years) 42.2 ± 9.5
BMI (Kg/m2) 30.2 ± 3.2
Fat mass (Kg) 33.9 ± 7.0
Free fat mass (kg) 45.8 ± 9.8
Android fat mass (%) 49.7 ± 6.1
apoA1 (g/L) 120.5 ± 25.8
apoB (g/L) 80.9 ± 24.9
Total-Cholesterol (mg/dl) 203.69 ± 37.53
HDL-Cholesterol (mg/dl) 52.64 ± 12.95
LDL-Cholesterol (mg/dl) 128.48 ± 31.8
Triglycerides (mg/dl) 112.87 ± 71.34
Glucose (mg/dl 89.96 ± 9.43
ABSI 6.12 ± 0.42
AIP 0.28 ± 0.27
Leptin (pg/mL) 218.6 ± 165.6
Adiponectin (ng/mL) 83.6 ± 49.6
Leptin/adiponectin 3.4 ± 3.5
GLP-1 1.3 ± 0.5
Grelin (pg/mL) 405.3 ± 253.3
C16:0 27.1 ± 2.6
C16:1 2.8 ± 0.9
C18:0 5.9 ± 0.8
C18:1 22.2 ± 3.6
C18:2 n-6 28.8 ± 4.4
C18:3 n-3 0.5 ± 0.2
C18:3 n-6 0.3 ± 0.2
C20:3 n-6 1.3 ± 0.3
C20:4 n-6 8.7 ± 1.7
C20:5 n-3 0.5 ± 0.3
C22:5 n-3 0.3 ± 0.2
C22:6 n-3 1.6 ± 0.5
AA/EPA 20.3 ± 10.2
Saturated fatty acids 33.1 ± 2.6
Monounsaturated fatty acids 24.9 ± 3.7
Polyunsaturated fatty acids (PUFA) 42 ± 5.02
Total omega-6 PUFA 39.1 ± 5.01
Total omega-3 PUFA 2.9 ± 0.8
omega-6/omega-3 14.3 ± 3.9
Plasma fatty acids are expressed as % of total content
API atherogenic index of plasma, ABSI body shape index, CRP c-reactive
protein, GLP-1 glucagon-like peptide-1, HOMA homeostatic model assessment
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Concerning fatty acid desaturase activity, the D6D and
D9D indices were unaffected by diet intervention. The
present observation regarding D6D agrees with previous
reports by Vessby [41]. The increased serum D5D
index found after diet intervention program is an
attractive and positive result, since a high D5D index
in serum predicts a reduced risk to develop the meta-
bolic syndrome [42], and as well as cardiovascular
death [43].
Previous study demonstrated that estimated desatur-
ase activities are closely associated with the features
of cardiometabolic risk in Koreans [43]. Our results
on the other hand have not shown correlations
between plasma fatty acid profile, estimated desatur-
ase activities and metabolic indices, but this mismatch
may be due to several factors: differences in the BMI
of subjects studied (normal weight in the study by
Do [44], overweight and obese subjects in the
present study), and difference in ethnicity since sig-
nificant ethnic differences has been found in desatur-
ase activities [45].
The significant increase of arachidonic acid, eicosa-
pentaenoic acid, docosahexaenoic acid, n-3 LCPUFA con-
tent, and a significant decrease of palmitoleic acid, n-6
LCPUFA/n-3 LCPUFA found in this study confirmed pre-
vious results indicating that serum lipids well reflect the
dietary fat intake, other than is also influenced by
desaturating enzymes [16].
Another innovative item of the study was a com-
parison of the plasma fatty acid profile and desaturase
activities among the group of overweight and obese.
We observed that obese subjects, compared to over-
weight subjects, show a significantly higher value of
oleic acid, monounsatured fatty acids, activity of
C18:0 delta 9 desaturase and a lower value of linoleic
acid, polyunsaturated fatty acids and long chain
omega 6 fatty acids.
Concerning fatty acid desaturases, the delta 9 desatur-
ase activity (SCD-1) is increased in obese compared to
overweight subjects, confirming data from literature: a
high SCD-1 activity has been associated with obesity
[46–48], and hypertriacylglycerolaemia [49].
Table 2 Baseline gender differences in fatty acid profile (% of total) and estimated desaturase activities
Variable F M Δ (95 %) P value
C16:0 26.9 ± 2.5 27.6 ± 2.8 −0.65 (−1.76, 0.46) 0.25
C16:1 2.8 ± 0.9 2.5 ± 0.7 0.30 (−0.08, 0.68) 0.13
C18:0 6.0 ± 0.8 5.7 ± 0.6 −0.29 (−0.04, 0.62) 0.09
C18:1 21.2 ± 2.8 24.6 ± 4.0 −3.33 (−4.70, −1.96) 0.00
C18:2 n-6 29.3 ± 4.3 27.5 ± 4.2 1.86 (0.01, 3.72) 0.05
C18:3 n-3 0.5 ± 0.2 0.5 ± 0.2 0.06 (−0.02, 0.14) 0.14
C18:3 n-6 0.3 ± 0.1 0.3 ± 0.2 −0.05 (−0.12, 0.01) 0.10
C20:3 n-6 1.4 ± 0.3 1.2 ± 0.3 0.16 (0.04, 0.28) 0.09
C20:4 n-6 9.1 ± 1.5 7.8 ± 1.9 1.32 (0.62, 2.02) 0.0003
C20:5 n-3 0.5 ± 0.3 0.6 ± 0.4 −0.05 (−0.17, 0.08) 0.45
C22:5 n-3 0.3 ± 0.2 0.3 ± 0.1 −0.001 (−0.07, 0.06) 0.97
C22:6 n-3 1.6 ± 0.5 1.5 ± 0.6 0.10 (−0.12, 0.32) 0.38
AA/EPA 21.2 ± 10.5 17.9 ± 9.0 3.32 (−1.02, 7.66) 0.13
Saturated fatty acids 33.0 ± 2.5 33.3 ± 2.8 −0.36 (−1.48, 0.75) 0.52
Monounsaturated fatty acids 24.1 ± 3.2 27.1 ± 4.1 −3.03 (−4.53, −1.53) 0.0001
Polyunsaturated fatty acids (PUFA) 43.0 ± 4.6 39.6 ± 5.2 3.40 (1.33, 5.46) 0.0015
Total omega-6 PUFA 40.0 ± 4.6 36.8 ± 5.3 3.29 (1.22, 5.35) 0.0021
Total omega-3 PUFA 3.0 ± 0.8 2.8 ± 1.0 0.11 (−0.24, 0.46) 0.55
omega-6/omega-3 14.4 ± 3.8 14.1 ± 4.2 0.25 (−1.44, 1.93) 0.77
Δ9 C16:0 Desaturase 0.1 ± 0.0 0.1 ± 0.0 0.01 (0.001, 0.03) 0.03
Δ9 C18:0 Desaturase 3.6 ± 0.7 4.4 ± 1.0 −0.75 (−1.10, −0.41) 0.00
Δ5 Desaturase 6.9 ± 1.9 6.6 ± 1.8 0.34 (−0.48, 1.15) 0.42
Δ6 Desaturase 0.0 ± 0.0 0.0 ± 0.0 −0.003 (−0.005, −0.0003) 0.03
Values in bold, p <0.05
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Moreover, a high SCD-1 activity has been also associ-
ated with the metabolic syndrome [42], as well as with
an increased risk to develop insulin resistance [41], car-
diovascular diseases and death [43].
Concerning gender-related differences, we found that
women, compared to men, show a significantly higher
value of AA, total PUFA, omega-6 PUFA, and a lower
value of MUFA, of delta-6 desaturase, C18:0 delta-9 and
C16:0 delta-9 desaturase activities.
The higher arachidonic acid level in woman could be
correlated to clinical observations and experimental find-
ings in humans that already demonstrated that humoral
and cell-mediated immune responses markedly differ
between sexes [50]. For example, women mount stronger
inflammatory and innate immune responses to bacterial
and viral infections or to vaccination [51]. The more pro-
nounced pro-inflammatory response pattern in women
relative to men is generally thought to be beneficial by
limiting pathogen spread and by accelerating pathogen
clearance. However, inflammatory and autoimmune dis-
eases are much more prevalent in women compared to
men [52]. Our data on CRP indicate that the nutritional
intervention is able to decrease inflammation in MHO
subjects together with the omega-6 /omega-3 ratio that is
considered a marker of inflammatory level related to the
lipids mediators derived from these polyunsaturated fatty
acids [53].
Table 3 Baseline differences in fatty acid profile and estimated desaturase activities in overweight and obese subjects
Variable BMI < 30 BMI >30 Δ (95 %) P value
C16:0 26.7 ± 2.3 27.6 ± 2.8 0.84 (−1.84, 0.16) 0.10
C16:1 2.6 ± 0.9 2.9 ± 0.9 −0.26 (−0.61, 0.08) 0.14
C18:0 6.0 ± 0.8 5.9 ± 0.7 0.16 (−0.15, 0.46) 0.31
C18:1 21.6 ± 3.3 22.9 ± 3.5 −1.36 (−2.72, 0.0018) 0.05
C18:2 n-6 29.7 ± 4.0 27.7 ± 4.5 2.06 (0.39, 3.73) 0.02
C18:3 n-3 0.5 ± 0.2 0.5 ± 2 0.03 (−0.04, 0.10) 0.42
C18:3 n-6 0.3 ± 0.2 0.3 ± 0.2 −0.0036 (−0.06, 0.06) 0.91
C20:3 n-6 1.4 ± 0.3 1.3 ± 0.3 0.04 (−0.07, 0.15) 0.43
C20:4 n-6 8.9 ± 1.5 8.5 ± 1.9 0.32 (−0.35, 1.00) 0.35
C20:5 n-3 0.5 ± 0.3 0.6 ± 0.3 −0.02 (−0.14, 0.1) 0.73
C22:5 n-3 0.3 ± 0.2 0.3 ± 0.1 0.03 (−0.03, 0.09) 0.27
C22:6 n-3 1.5 ± 0.4 1.7 ± 0.6 −0.16 (−0.36, 0.04) 0.12
AA/EPA 20.2 ± 9.5 20.3 ± 11.0 −0.09 (−4.08, 3.91) 0.97
Saturated fatty acids 32.7 ± 2.4 33.4 ± 0.8 −0.68 (−1.69, 0.33) 0.18
Monounsaturated fatty acids 24.2 ± 3.4 25.8 ± 4.0 −1.62 (−3.06, −0.19) 0.03
Polyunsaturated fatty acids (PUFA) 43.1 ± 4.5 40.8 ± 5.3 2.31 (0.38, 4.23) 0.02
Total omega-6 PUFA 40.2 ± 4.5 37.8 ± 5.3 2.42 (0.51, 4.34) 0.01
Total omega-3 PUFA 2.9 ± 0.7 3.0 ± 0.9 −0.12 (−0.44, 0.20) 0.47
omega-6/omega-3 14.8 ± 3.7 13.7 ± 4.0 1.06 (−0.46, 2.58) 0.17
Δ9C16:0 Desaturase 0.1 ± 0.03 0.1 ± 0.03 −0.01 (−0.02, 0.004) 0.21
Δ9C18:0 Desaturase 3.7 ± 0.8 4.0 ± 0.9 −0.34 (−0.68, −0.002) 0.04
Δ5 Desaturase 6.8 ± 1.9 6.8 ± 2.0 0.05 (−0.69, 0.80) 0.88
Δ6 Desaturase 0.01 ± 0.01 0.01 ± 0.01 −0.0007 (−0.002, 0.001) 0.47
Values in bold, p <0.05
Table 4 Intake of macronutrients before and at the end of
two-months of well balanced intervention diet
Daily nutritional intake Pre treatment Post treatment
Energy (kJ/day) 8985.3 ± 70.4 6792 ± 64.5
Protein (% of energy) 16.2 ± 1.0 17.5 ± 3.2
Carbohydrates (% of energy) 52.6 ± 2.1 54.4 ± 1.9
Fat (% of energy) 31.2 ± 2.1 26.1 ± 1.9
Saturated fatty acids (% of energy) 12.7 ± 2.9 7.1 ± 1.0
Cholesterol (mg) 213 ± 32.4 178.6 ± 30.5
Fiber (g/d) 16.8 ± 7.9 26.5 ± 3.6
Mean ± SD; nutritional evaluation carried out by Carnovale E. Marletta L. “Food
composition tables”, Italian National Institute of Nutrition, Rome 1997
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Gender differences have been previously reported in
obese subjects also for delta-9 desaturase, with higher ac-
tivity in women than men. Moreover, Warensjo et al. re-
ported that women have significantly higher levels of
delta-6 desaturase activities than men [19]. Our results are
therefore in contrast to this previous study. However, the
populations studied are very different (normal weight
subjects involved in moderate physical activity for the
research by Warensjo and sedentary MHO subjects in our
study) and this could explain these differences.
The main limitation of our study is due to the lack of
genetic factor assessment since studies on monozygotic
twins have indicated that the conservation and distribu-
tion of fatty acids are subject to considerable genetic
variance in humans [54].
Further studies are therefore needed on this specific
MHO population, even going to compare the plasma
fatty acid profile and desaturase activities of MHO sub-
jects with non MHO group.
In conclusion, the prudent diet intervention was ef-
fective in improving metabolic indices and these findings
reinforce the hypothesis that MHO subjects would also
benefit from a lifestyle weight reduction program. More-
over, the high serum D5D index found after diet
Table 5 Fatty acid profile and estimated desaturase activities studied before and after 2-months of well-balanced diet intervention
Variable Pre treatment Post treatment Δ (95 %) P value Multivariable p valuea
C16:0 26.8 ± 2.4 26.6 ± 2.6 −0.16 (−0.69 to 0.35) 0.53 0.08
C16:1 2.7 ± 0.9 2.5 ± 0.9 −0.16 (−0.32 to −0.01) 0.038 0.017
−0.20 (−0.37 to −0.04)a
C18:0 5.9 ± 0.8 6.0 ± 0.9 −0.05 (−0.14 to 0.25) 0.59 0.93
C18:1 22.4 ± 3.6 22.3 ± 3.8 −0.10 (−0.86 to 0.65) 0.79 0.79
C18:2 n-6 28.7 ± 4.5 28.3 ± 3.9 −0.44 (−1.25 to 0.38) 0.28 0.22
C18:3 n-3 0.5 ± 0.2 0.5 ± 0.5 0.05 (−0.06 to 0.15) 0.38 0.43
C18:3 n-6 0.3 ± 0.1 0.3 ± 0.3 0.04 (−0.01 to 0.10) 0.14 0.09
C20:3 n-6 1.4 ± 0.3 1.3 ± 0.3 −0.04 (−0.09 to 0.00) 0.06 0.019
−0.07 (−0.12 to −0.01)a
C20:4 n-6 8.9 ± 1.6 9.3 ± 1.9 0.45 (0.12 to 0.77) 0.007 0.001
0.64 (0.28 to 1.00)a
C20:5 n-3 0.6 ± 0.3 0.7 ± 0.4 0.09 (0.01 to 0.17) 0.030 0.007
0.11 (0.03 to 0.19)a
C22:5 n-3 0.3 ± 0.2 0.3 ± 0.1 0.01 (−0.03 to 0.05) 0.69 0.33
C22:6 n-3 1.6 ± 0.5 1.9 ± 0.6 0.23 (0.13 to 0.33) <0.001 <0.001
0.29 (0.18–0.34)a
AA/EPA 20.1 ± 10.4 19.4 ± 11.8 −0.62 (−2.80 to 1.55) 0.57 0.47
Saturated fatty acids 32.7 ± 2.4 32.6 ± 2.9 −0.11 (−0.74 to 0.51) 0.72 0.15
Monounsaturated fatty acids 25.1 ± 3.8 24.8 ± 3.9 −0.27 (−1.05 to 0.51) 0.50 0.79
Polyunsaturated fatty acids (PUFA) 42.2 ± 5.0 42.6 ± 4.7 0.38 (−0.65 to 1.41) 0.47 0.27
Total omega-6 PUFA 39.2 ± 5.1 39.2 ± 4.6 0.01 (−0.99 to 1.01) 0.99 0.81
Total omega-3 PUFA 3.0 ± 0.8 3.4 ± 1.0 0.37 (0.17 to 0.57) <0.001 <0.001
0.46 (0.26 to 0.66)a
omega-6/omega-3 14.0 ± 4.0 12.6 ± 4.0 −1.37 (−2.16 to −0.57) 0.001 <0.001
−1.67 (−2.47 to −0.88)a
Δ 9C16:0 Desaturase 0.1 ± 0.0 0.1 ± 0.0 −0.01 (−0.01 to 0.00) 0.09 0.09
Δ9C18:0 Desaturase 3.9 ± 0.9 3.9 ± 1.1 −0.03 (−0.2 to 0.18) 0.77 0.74
Δ5 Desaturase 7.0 ± 1.9 7.8 ± 2.4 0.71 (0.35 to 1.08) <0.001 <0.001
0.96 (0.57 to 1.35)a
Δ6 Desaturase 0.01 ± 0.01 0.01 ± 0.01 0.002 (−0.000 to 0.004) 0.10 0.06
aAdjusted for gender and BMI groups. Values in bold, p <0.05
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intervention program is an attractive result, since it pre-
dicts a reduced risk to develop the metabolic syndrome
as well as cardiovascular death.
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